[Antiangiogenic therapy].
Tumor vasculature is a promising novel target for anticancer treatment. Natural or synthetic products have been developed, and endogenous inhibitors such as angiostatin have been extensively analyzed. Several inhibitors are currently under investigation, and many compounds are tested in pre-clinical trials. This review provides an overview of the antiangiogenic treatments as well as early clinical result with these agents.
Toi
M
M
Dept. of Surgery, Tokyo Metropolitan Komagome Hospital, Japan.
D043168:Angiostatins; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D003094:Collagen / Q000627:therapeutic use; D043169:Endostatins; D016228:Endothelial Growth Factors / Q000627:therapeutic use; D006801:Humans; D008222:Lymphokines / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D051379:Mice; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D010446:Peptide Fragments / Q000627:therapeutic use*; D010958:Plasminogen / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D043169:Endostatins; D016228:Endothelial Growth Factors; D008222:Lymphokines; D010446:Peptide Fragments; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D043168:Angiostatins; D010958:Plasminogen; D003094:Collagen; D017258:Medroxyprogesterone Acetate